Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
filingDate |
2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76610e1e1fe88d4ce4b3854f46731edd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e65f50862c48d4aaec00394220ac78a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af226973a2cded1df8049b2cdb9fa5d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e38bdefd89cb88662c618f6445a7e66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96730552229867423c5c53a88dc312a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d279153ea617123f26ba641a95f8ac4 |
publicationDate |
2010-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20100085067-A |
titleOfInvention |
Anti-glycancan-3 antibody with improved reaction rate in plasma |
abstract |
Method for controlling plasma half-life of anti-glycancan 3 antibody, Pharmaceutical composition comprising anti-glycancan 3 antibody with controlled plasma half-life as active ingredient, Method for preparing anti-glycancan antibody and Anti-glypican as active ingredient There is provided a pharmaceutical composition comprising 3 antibodies. A method of controlling plasma half-life of an anti-glycancan 3 antibody by modifying an amino acid residue exposed on the surface of the anti-glycancan 3 antibody; And an anti-glycancan 3 antibody whose plasma half-life is controlled by amino acid residue modification, a pharmaceutical composition comprising an anti-glycancan 3 antibody as an active ingredient, and a method for preparing an anti-glycancan 3 antibody and an anti- Provided are methods of producing a pharmaceutical composition comprising a Glypican 3 antibody. |
priorityDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |